Enterprise Value

523.7M

Cash

320.1M

Avg Qtr Burn

-54.52M

Short % of Float

10.82%

Insider Ownership

7.91%

Institutional Own.

92.98%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
ABBV-RGX-314 (Subretinal Delivery) Details
Eye disease , Wet age-related macular degeneration , Age-related macular degeneration

Phase 2

Data readout

ABBV-RGX-314 (Suprachoroidal Delivery) Details
Eye disease , Wet age-related macular degeneration , Age-related macular degeneration

Phase 2

Data readout

ABBV-RGX-314 (Suprachoroidal Delivery) Details
Diabetes, Eye disease , Diabetic retinopathy

Phase 2

Data readout

RGX-121 Details
Rare diseases, Mucopolysaccharidosis type II, Pulmonary arterial hypertension, Lung disease, Genetic disorder, Rare genetic disease, Mucopolysaccharidoses

Phase 1/2

Data readout

RGX-381 Details
Central nervous system illness

Phase 1/2

Data readout

RGX-202 Details
Rare diseases, Genetic disorder, Rare genetic disease, Duchenne muscular dystrophy

Phase 1/2

Data readout

RGX-111 Details
Rare diseases, Genetic disorder, Mucopolysaccharidoses, Rare genetic disease, Mucopolysaccharidosis Type 1

Phase 1/2

Update

RGX-181 Details
Central nervous system illness, Batten Disease

Phase 1

Data readout